#South Korea #Seoul #Seegene #Springer Nature #MDx Grants

Seegene and Springer Nature Announce 2025-2026 Nature Awards MDx Impact Grants

In a significant initiative aimed at tackling one of the most pressing challenges in global public health, Seegene Inc., a leader in molecular diagnostics, has teamed up with Springer Nature to announce the 2025-2026 Nature Awards MDx Impact Grants. This year, the focus will be on antibiotic resistance in urinary tract infections (UTI-DR), a critical area requiring urgent attention and innovative solutions.

The Goals of the Program

Launched on September 10, 2025, the Nature Awards MDx Impact Grants program invites researchers worldwide to submit proposals for developing innovative products and clinical studies. Researchers are encouraged to target up to 18 resistance genes associated with urinary infections, reflecting a growing urgency to address unmet clinical needs in this domain.

The application window is open until November 20, with winners set to be announced in August 2026. Selected researchers will receive up to $600,000 in funding for their projects. They will also gain access to Seegene's syndromic PCR tests, tools, and software, further supporting the development of new diagnostic solutions.

Aiming for Global Impact

Richard Hughes, Vice President of Editorial at Springer Nature, spoke about the program's intent to foster collaboration among scientists and stimulate innovative research. He emphasized that by supporting researchers in developing diagnostic solutions, they can significantly enhance healthcare worldwide.

Dr. Jik Young Park, Vice President and Head of the RD Division at Seegene, added that the collaboration aims to provide scientists and researchers with the necessary tools and technologies to turn innovative ideas into practical solutions. By sharing their syndromic PCR technologies and funding, they hope to accelerate the advancement of molecular diagnostics and work toward a vision of a world free from diseases.

Previous iterations of the Nature Awards MDx Grants program have successfully supported essential projects. The 2024-2025 funding round backed projects focused on rapidly identifying ViruResist Klebsiella pneumoniae and utilizing multiplex PCR tests to detect viral infections in immunocompromised patients.

Who is Seegene?

Seegene Inc. is recognized globally for its contributions to molecular diagnostics, boasting over 20 years of experience in research and development, manufacturing, and marketing of syndromic technologies based on real-time PCR. During the COVID-19 pandemic, Seegene supplied more than 340 million tests across over 100 countries, underscoring its international impact.

The company's exclusive quantitative syndromic PCR technology enables simultaneous detection of 14 pathogens causing similar clinical signs and symptoms within a single reaction tube. Through multi-tube panels, coverage can be expanded to include dozens of clinically relevant agents. This technology not only identifies co-infections but also provides quantitative data, offering an invaluable advantage in managing complex infections.

Through its Technology-Sharing Initiative, Seegene merges its quantitative syndromic PCR technology with the Seegene Digitalized Development System (SGDDS) to co-develop tailored diagnostic products alongside institutions and international experts. By fostering global collaboration, Seegene strives for a world free from all diseases.

For further insights into Seegene and its innovative technologies, visit their website at Seegene.com and follow the company on LinkedIn at linkedin.com/company/seegene-inc.

About Nature Portfolio

Nature Portfolio provides cutting-edge products and services in biological, physical, chemical, and applied sciences to support the scientific community. Founded in 1869, Nature is the premier weekly scientific journal globally. Nature Portfolio also encompasses Nature Research journals, the multidisciplinary open-access journal Nature Communications, and several other open-access publications like Scientific Reports. With over nine million monthly visitors, nature.com delivers a wealth of resources, including news, commentary, insights, and Nature Careers, a leading portal for scientific career opportunities.

For more information about Nature Portfolio, visit nature.com and follow @Nature on social media.